IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Divisional Under 37 C.F.R. 1.53(b) Application of: Bach et al.

Prior Application Serial No.: 09/125,168

Prior Filing Date: 18 August 1998

Prior Group Art Unit: 1646 Examiner: Joseph F. Murphy

For: USE OF IL-7 FOR TREATING AUTOIMMUNE DISEASES AND INSULIN DEPENDENT DIABETES

MELLITUS IN PARTICULAR

Mail Stop Patent Applications Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

CERTIFICATE UNDER 37 C.F.R. 1.10

Express Mail Label Number: EL676469475US

Signature

CITATION OF REFERENCES

Enclosed herewith on an Information Disclosure Statement by Applicant (Form PTO-1449) is a list of references for consideration by the Examiner.

This Information Disclosure Statement is being filed concurrently with the above-identified application and, consequently, no fee or statement pursuant to 37 C.F.R. §1.97(c) or (d) is required. Furthermore, pursuant to 37 C.F.R. §1.98(d), copies of the listed references are not being provided as they were previously cited by or submitted to the Examiner in prior application Serial No. 09/125,168, filed August 18, 1998 which are relied upon for an earlier filing date under 35 U.S.C. §120.

Paul E. Dupont $^{\nu}$ Reg. No. 27,435

Date:

Address:

Patent Department Sanofi-Synthelabo Inc. 9 Great Valley Parkway Malvern, PA 19355

Telephone No. (610) 889-6338 Facsimile: (610) 889-8799

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copyof this form with next communication to applicant.

Bach et al., The NOD Mouse, Re. Immunol. 1997 vol. 148, pp. 285-366 Morrow, WJ et al., Clin Immunol Immunopathol. 1991 Feb 58(2) p. 163-80

EXAMINER

C.R. Acad. Sci. Paris, Sciences de la vie/Life Sciences, vol. 319, pp. 125-129, 1996

DATE CONSIDERED